Afficher la couverture 'Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma. | Bertaut, Aurelie' en grand format
/5

0 avis

Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.

Archive ouverte

Bertaut, Aurelie | Boidot, Romain | Madkouri, Rachid | Kaderbhai, Coureche Guillaume | Vincent, Julie | Chauffert, Bruno | Ghiringhelli, Francois

Edité par CCSD -

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, JUN 03-07, 2016. International audience

Consulter en ligne

Suggestions

Du même auteur

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

Archive ouverte | Bertaut, Aurélie | CCSD

IF 5.008 . International audience. Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then be...

Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Archive ouverte | Madkouri, Rachid | CCSD

IF 7.719. International audience. Background: Interest is growing on immune cells involvement in central nervous system tumors such as glioblastoma. Even if a few reports highlighted that immune classifications coul...

Implementation and use of whole exome sequencing for metastatic solid cancer

Archive ouverte | Réda, Manon | CCSD

BACKGROUND : Genomically-guided clinical trials are performed across different tumor types sharing genetic mutations, but trial organization remains complex. Here we address the feasibility and utility of routine somatic and const...

Chargement des enrichissements...